Oura has agreed to purchase clinical artificial intelligence startup Counsel Health in a deal valued at $625 million. The acquired company previously disclosed $36 million in funding to develop an AI chatbot that triages user concerns. After engaging with users, the technology transfers them to clinicians for telehealth diagnosis and subsequent treatment. This move accelerates the push to integrate daily wearable metrics directly into professional healthcare workflows.
Key points
Counsel Health uses an AI chatbot to discuss medical issues before routing users to clini…: Counsel Health uses an AI chatbot to discuss medical issues before routing users to clinicians for diagnosis.
The major acquisition reflects an accelerating effort to connect consumer wearable hardwa…: The major acquisition reflects an accelerating effort to connect consumer wearable hardware with direct clinical services.
The transaction signals high industry conviction regarding the vital role of artificial i…: The transaction signals high industry conviction regarding the vital role of artificial intelligence in modern telehealth delivery.
Sources checked by our analysis pipeline: 1
Oura, the smart ring maker that just over a month ago delayed plans to go public over market uncertainty, announced it will spend $625 million to acquire Counsel Health, a clinical artificial intelligence startup.
Counsel Health is the maker of a chatbot that users can talk with about health concerns before being transferred to a clinician for treatment and diagnosis over telehealth.The company had previously disclosed $36 million in funding.
The large transaction reflects a growing desire to connect consumer wearable devices to clinical care as well as conviction that AI chatbots will be an important part of health care.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Wearable technology developer Oura has reached an agreement to bring Counsel Health under its corporate umbrella. The high-value transaction represents an expenditure of $625 million to complete the corporate purchase. This strategic corporate move binds the smart ring producer directly to the acquired health entity.
The chipmaker's leadership faces unprecedented internal scrutiny as corporate governance officials evaluate potential security risks surrounding top executive conduct. Even firm skeptics warn that destabilizing corporate leadership at this juncture would trigger broad negative repercussions across the market. The situation leaves investors weighing governance concerns against the risks of abrupt executive turnover.
The technology giant is restricting immigration support across a major business segment, fundamentally altering its talent acquisition strategy. This shift directly curtails employment pathways for international talent pursuing authorization through the company. Consequently, current foreign employees and prospective candidates face significantly reduced options for obtaining corporate backing.